Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK/PD of Single Rising Oral Doses of BI 44847 in Healthy Males
NCT02209844Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Aug 2006
- Primary completion
- Jan 2007
- Modality
- Small Molecules
01
Overview
Phase 1, randomised, double-blind trial in type 2 diabetes mellitus (T2DM) comparing BI 44847 with Placebo (2 arms). Primary endpoints: Number of patients with adverse events, Number of patients with clinically significant findings in vital signs and 3 more. Started Aug 2006; status: completed.
02
Drugs
BI-44847
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT02209844.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02209844.